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Abstract. In sporadic Alzheimer’s disease (AD), cerebrospinal fluid (CSF) analysis is becoming increasingly relevant to establish
an early diagnosis. We present a case of familial AD due to a presenilin-1 mutation in which CSF studies suggested appropriate
DNA diagnostics. A 38 year old Dutch man presented with dementia, spastic paraparesis, and frontal executive function
impairments, mimicking familial Creutzfeldt Jakob disease and frontotemporal dementia. CSF studies, revealing increased total
tau and phosphorylated-tau levels with decreased amyloid-β42, distinguished familial AD from Creutzfeldt Jakob disease and
frontotemporal dementia. A causative p.L424R PSEN1 mutation was subsequently identified.
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INTRODUCTION
The ante mortem diagnosis of Alzheimer’s disease
(AD) has traditionally been based on clinical criteria
that have insufficient sensitivity in the early phases (AD
pathology is often present years before clinical symp-
toms appear) and lack specificity [1,2]. In the last de-
cennium, however, cerebrospinal fluid (CSF) diagnos-
tic studies have been established as an important tool
for an early and specific differential diagnosis of de-
mentia syndromes [2–4]. Combined analysis of CSF
biomarkers results in higher specificity and sensitivity
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than clinical criteria alone in distinguishing AD from
Creutzfeldt-Jakob disease (CJD), frontotemporal de-
mentia (FTD), vascular dementia, dementia with Lewy
bodies (DLB), and Parkinson’s disease dementia [3,4].
The most important CSF biomarkers for these various
dementia-associated disorders are presented in Table 1.
Also in cases of clinical mild cognitive impair-
ment, decreased CSF levels of Aβ42, together with ele-
vated total-tau and phosphorylated-tau concentrations,
helped to predict the conversion to AD [5].
In patients with early-onset or familial Alzheimer’s
disease (FAD), a diagnosis is usually made according
to clinical criteria, a positive family history with multi-
ple affected members, and by DNA testing. Currently,
three autosomal dominant inherited genes have been
identified: the amyloid-β precursor protein (AβPP)
gene on chromosome 21; the presenilin-1 (PSEN1)
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Table 1
CSF biomarkers in different dementia syndromes
Reference values according Aβ42 levels (ng/L) t-tau (ng/L) p-tau181 (ng/L)
to the patient’s age: age <15: n > 400 age 15–50: n < 300 age >15: n <85
age > 15: n > 500 age 51–85: n < 350
Alzheimer’s disease ↓↓ ↑↑ ↑↑
Creutzfeldt-Jakob disease ↓ ↑↑↑>1500 N
Frontotemporal dementia N/(↓) variable N/↑
Vascular dementia N/(↓) N/(↑) N
Dementia with Lewy bodies ↓ N/(↑) N
N: normal, ↑: increased, ↓: decreased, Aβ42: amyloid β 42 protein; t-tau: total tau; p-tau181: tau
phosphorylated at threonine 181.
For determination of reference values of Aβ42, total tau and p-tau levels, patients were included
with ages below 50 years (n = 129) and with ages 50–85 years (n = 50), who were referred
to the Department of Neurology and underwent a lumbar puncture in a diagnostic work-up, but
who, after extensive examination, turned out not to have a neurological disease, and who had
normal CSF cell count, hemoglobin, bilirubin, total protein, lactate, glucose, and no oligoclonal
IgG bands [4]. Comparable values were published by Sjogren et al. [18].
gene on chromosome 14; and the presenilin-2 (PSEN2)
gene, on chromosome 1. More than 50% of FAD cases
can be ascribed to a PSEN1 mutation, with more than
160 different mutations having already been identified
(http://www.molgen.ua.ac.be/Admutations) [6]. The
fact that PSEN1 associated dementia is genetically and
clinically heterogeneous can hamper an appropriate di-
agnosis. The following case report demonstrates that
CSF biomarker analysis may facilitate this diagnosis
and may allow a rapid selection of relevant and conclu-
sive mutation analysis.
CASE REPORT
A 38 year old man was referred to the outpatient
clinic with progressive memory complaints and gait
difficulties for 8–9 months. The patient himself denied
memory problems but his relatives had noticed incipient
memory impairment. The patient had recently given
up his job as a security officer in a private company.
His father recognized these signs as similar to those of
his deceased wife, who started having cognitive decline
and gait difficulties at the age of 35. She had died at
the age of 39, severely demented, wheel-chair bound,
and suffering from epilepsy and hallucinations. The
grandfather of the index-patient, who suffered from a
similar disease, had died in his late thirties.
On neurological examination the index-patient re-
vealed bradyphrenia, mild impairment of execu-
tive functions such as decreased initiation and self-
generation, a slurred speech, leg hypertonia, and sym-
metric brisk reflexes that were more pronounced in the
lower extremities, with bilateral Babinski sign. His gait
was both spastic and ataxic. The Mini Mental State
Examination (MMSE) score was 24/30.
The following autosomal dominant (AD) degenera-
tive diseases were considered in the differential diag-
nosis: familial CJD, FTD, FAD, and hereditary spastic
paraparesis with cognitive impairment (SPAST).
Routine hematological and serum biochemical stud-
ies were all normal. Brain magnetic resonance imag-
ing revealed bilateral posterior parietofrontal atrophy,
without white matter abnormalities (Fig. 1).
CSF was obtained by lumbar puncture, collected in
polypropylene tubes, and transferred to the hospital lab-
oratory within 30 minutes. Routine analysis revealed
a normal leukocyte count and a slightly elevated pro-
tein concentration (598 mg/L) (reference range: 240–
490 mg/L). After centrifugation, small aliquots of the
CSF were frozen at −80◦C until analysis of Aβ42, to-
tal tau, and phosphorylated tau (p.Thr181) (p-tau) pro-
tein (using commercial assays,Innogenetics, Gent, Bel-
gium). These analyses showed an increased p-tau con-
centration (217 ng/L; reference range <85 ng/L) and
increased total tau protein concentration (1382 ng/L;
reference range <300 ng/L); whereas the Aβ42 con-
centration was decreased (380 ng/L; reference range
>500 ng/L). For the establishment of reference values
of Aβ42, total tau, and p-tau levels, see the legend of
Table 1.
Whole gene sequencing of the PRNP (for famil-
ial CJD), MAPT (for FTD), and SPAST genes re-
vealed no mutations. Sequencing of the PSEN1 gene
identified the p.L424R (NM 000021.2: c.1271T>G,
p.Leu424Arg) missense mutation in exon 12. After
identifying this PSEN1 mutation, PSEN2 and AβPP
(less frequent forms of FAD) analysis was considered
redundant.
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Fig. 1. Cerebral magnetic resonance imaging of the patient described: A + B transversal images: bilateral posterior parietofrontal atrophy,
without white matter abnormalities; C: coronal image: bilateral parietofrontal and temporal atrophy.
DISCUSSION
In the more than 160 mutations in the PSEN1 gene
that are currently known to cause FAD, many different
signs and symptoms may accompany early onset de-
mentia [6, (http://www.molgen.ua.ac.be/Admutations)].
The following have been reported: myoclonus, general-
ized epileptic seizures, psychiatric disturbances, frontal
executive function impairments, spastic paraparesis,
extrapyramidal and cerebellar signs, and early onset
aphasia with relatively spared naming skills [7,8]. In
individual cases, the clinical distinction between FAD
and familial CJD or between FAD and FTD may be
difficult [8]. Hereditary spastic paraparesis with cogni-
tive impairment is described as a complicated form of
SPAST [9]. This autosomal dominant disorder can also
resemble FAD with spastic paraparesis in the beginning
of the disease. Because the cognitive decline in SPAST
(which may be present before the onset of spastic para-
paresis) is usually relatively mild, a rapidly progressive
dementia would reject this differential diagnose. In
this case, a diagnosis of SPAST associated disease was
rejected, considering the rapidly progressive dementia
of the mother.
A patient such as ours, who presents with such an
extensive autosomal dominant neurodegenerative dis-
ease, requires consideration of at least four different
diagnoses with subsequent costly and time consuming
(4–6 months) sequencing efforts in four (or more) dif-
ferent genes. Clearly, ancillary investigations such as
CSF studies (which may be obtained in less than two
weeks) may aid in selecting appropriate priorities for
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gene sequencing efforts. In retrospect, the CSF ab-
normalities we found, interpreted as being typical for
AD, should have suggested to us to initially restrict our
DNA diagnostic resources to PSEN1 mutation analysis
or mutation analysis of other genes involved in AD.
CSF biomarkers abnormalities have been demon-
strated before in a few studies of presymptomatic car-
riers of PSEN1 mutations. In a study with six asymp-
tomatic PSEN1 mutation carriers, very low CSF Aβ42
levels where demonstrated [10]. In another report a
PSEN1 patient was described presenting with mild cog-
nitive impairment and later developing probable AD,
without other neurological signs [11]. This patient had
elevated CSF total tau and p-tau concentrations. Re-
cently, all three biomarkers were evaluated in preclini-
cal PSEN1 mutation carriers compared to non-mutation
carriers, showing a reduced Aβ42 to Aβ40 ratio in CSF
together with elevated CSF total tau and p-tau concen-
trations [12]. Our patient represents an already symp-
tomatic case, where these AD specific CSF biomark-
ers alterations preceded DNA results and demonstrat-
ed their use in distinguishing a clinical diagnosis of
PSEN1 FAD from familial CJD and FTD.
The p.L424R (p.Leu424Arg) missense mutation in
exon 12 has been described as a pathogenic mutation
previously, in one family from Poland [13]. Our pa-
tient had a similar age of onset (30–35 years) and his
mother had a similar progression to death (4–5 years)
as in the described family. In contrast, these published
cases had typical AD, without additional neurological
deficits. Our family with a p.L424R mutation revealed
a much more diverse phenotype, with spastic parapare-
sis, frontal executive function impairment, epilepsy,
and psychiatric symptoms all occurring in one fami-
ly. In contrast to the p.L424R mutation, the p.L424H
(p.Leu424His) mutation has been found more often,
for example in a French family and in a Polish fami-
ly [14,15]. The last one is associated with a clinical
phenotype of variant AD with strong FTD signs, like
frontal deficits, personality changes and social inhibi-
tion, and some DLB signs, such as early visual halluci-
nations [15]. Another Leu424Phe (p.L424F) mutation
was found in a Bulgarian family with marked behav-
ioral abnormalities with dementia and an age of onset
around 60 years [16]. This strongly suggests that oth-
er genetic and epigenetic and possibly environmental
factors may contribute to phenotypic heterogeneity in
PSEN1 associated FAD. Apparently, the actual local-
ization of the mutation within the PSEN1 gene appears
largely unpredictive for the resulting phenotype, thus
demonstrating a lack of genotype-phenotype correla-
tion in PSEN1 associated disease [17].
Although no functional studies have been performed
on the p.L424R mutation, it is considered pathogenic.
The p.L424R and p.L424H mutations were not present
in a panel of 400 Dutch control chromosomes (D. Dooi-
jes, unpublished). P.L424R has been previously de-
scribed to be completely segregated with FAD in a large
Polish family [13]. The PSEN1 p.L424H/F mutations,
described in another Polish FAD family, a French fam-
ily, and a Bulgarian family, affects the same Leucine
amino acid residue at position 424 of the PSEN1 pro-
tein that is affected by the p.L424R mutation [14–16].
P.Leu424 is located in exon 12 which encodes a struc-
turally conserved and a functionally important domain
in which various pathogenic mutations have been de-
scribed. This leucine residue is located in a critical re-
gion of the transmembrane domain of the PSEN1 pro-
tein. By modeling the impact of a substitution on this
transmembrane domain and by using control groups,
silent polymorphisms could successfully be discrimi-
nated from disease-causing mutations [15]. Further-
more, a computer prediction algorithm predicts both
the p.L424R mutation and the p.L424H mutation to be
pathogenic (http://sift.jcvi.org/).
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